COMMUNIQUÉS West-GlobeNewswire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
16/05/2024
Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH SAN MATEO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Sagimet [...]
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
16/05/2024
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform [...]
Halo Dental Technologies Opens Waitlist for Its New Digital Mirror at California Dental Association Annual Conference
16/05/2024
Waitlist for the first-of-its-kind digital dental mirror opens May 16, 2024, for dentists and hygienists who want to be among the first to secure the Halo Digital Mirror MONTREAL, May 16, 2024 (GLOBE NEWSWIRE) -- Halo [...]
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
16/05/2024
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer [...]
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
16/05/2024
Collaboration leverages Totus’ covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas EMERYVILLE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- [...]
Cannabix Technologies and Omega Laboratories Inc. Enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology
16/05/2024
VANCOUVER, British Columbia, May 16, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) reports that it has entered into a strategic [...]
Chiesi to Present New Data Showcasing Depth of Respiratory Leadership at the American Thoracic Society 2024 International Conference
16/05/2024
Presentations will highlight new data in respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD) Data to be presented include new six-month results from a study of a single-inhaler [...]
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
16/05/2024
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory [...]
Scorpius Holdings Commends Congress on Bipartisan Legislative Action Aimed at Bolstering U.S. Biomanufacturing
16/05/2024
Urges Congress to Immediately Pass the BIOSECURE Act DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and [...]
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
16/05/2024
WINNIPEG, Manitoba, May 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of [...]
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter
16/05/2024
NAPLES, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. ( OTCQB: HLYK ), a leading provider of healthcare networking and technological innovation, has reported its financial results for the first [...]
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
16/05/2024
Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 Recent Type C CMC meeting with the U.S. [...]
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
16/05/2024
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis suppurativa to use the [...]
EDAP Reports First Quarter 2024 Financial Results
16/05/2024
Strong Q1 2024 U.S. Focal One ® HIFU procedure growth of +92% year-over-year Q1 2024 HIFU revenue of EUR 5.8 million ($6.3 million USD), an increase of 10.2% over Q1 2023 Q1 2024 total revenue of EUR 14.9 million ($16.1 [...]
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
16/05/2024
SARASOTA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced an update on [...]
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
16/05/2024
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long- [...]
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
16/05/2024
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib [...]
South Rampart Pharma Publishes SRP-001's Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports
16/05/2024
SRP-001 is a novel, non-opioid new chemical entity without abuse, liver, and kidney toxicities present in current pain medications Publication introduces SRP-001 as a safer alternative to existing pain medications SRP- [...]
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
16/05/2024
Sol-Gel to receive a total consideration of up to US$15 million, out of which US$10 million will be paid as upfront and regulatory milestones NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, [...]

Pages